ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
Data from the Phase II ELM-2 trial was presented at the American Society of Hematology (ASH) 2024 Annual Meeting, held…
Oncology
-
-
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the US Food and Drug Administration (FDA), marking “an important milestone” in…
-
NCCN visits Vietnam in continued cancer care collaboration
Leaders from the National Comprehensive Cancer Network (NCCN) alliance of US cancer centres are in Vietnam today (1 November) as…
-
Bladder cancer diagnoses to top 300,000 in major markets by 2033
The number of incident cases of bladder cancer in the eight major markets is set to increase, with men and…
-
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Lyell Immunopharma has entered a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotechnology company specialising in chimeric antigen…
-
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
TIGIT inhibitors have long been in a difficult race toward the finish line on the non-small cell lung cancer (NSCLC)…
-
IN8bio cuts staff and pipeline to focus on AML cell therapy
IN8bio, formerly Incysus Therapeutics, has instituted cash-saving measures to funnel resources into advancing its acute myeloid leukaemia (AML) allogenic cell…
-
Adcendo and Multitude ink ADC deal potentially worth $1bn
The antibody drug conjugate (ADC) dealmaking trend has seen yet another example as Adcendo has signed a licencing agreement potentially…
-
Phanes acquires second FDA orphan designation for bispecific antibody
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Phanes Therapeutics’ PT217 in neuroendocrine carcinoma…
-
Era of ADCs: Pharma companies innovate to stand out in a buzzing market
Antibody drug conjugates (ADCs) have taken over the cancer clinical research and dealmaking landscape, with new partnerships and agreements being…
